| Identification | Back Directory | [Name]
MI-538 | [CAS]
1857417-10-7 | [Synonyms]
MI-538
MI538; MI 538
MI538,inhibit,Epigenetic Reader Domain,Inhibitor,MI-538,MI 538
1H-Indole-2-carbonitrile, 6-hydroxy-1-(1H-pyrazol-4-ylmethyl)-5-[[4-[[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]-1-piperidinyl]methyl]- | [Molecular Formula]
C27H25F3N8OS | [MDL Number]
MFCD30532690 | [MOL File]
1857417-10-7.mol | [Molecular Weight]
566.6 |
| Chemical Properties | Back Directory | [Boiling point ]
812.0±65.0 °C(Predicted) | [density ]
1.56±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (176.49 mM);Water : < 0.1 mg/mL (insoluble) | [form ]
Solid | [pka]
9.46±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
MI-538 is an inhibitor of the interaction between menin and MLL fusion proteins with an IC50 of 21 nM. | [in vivo]
Treatment with MI-538 results in a pronounced, about 80%, reduction in the MV4;11 tumor volume, without causing substantial signs of toxicity reflected by less than 10% reduction of the body weight. MI-538 demonstrates markedly improved exposure (area under the curve, AUC, values), Cmax (maximum compound concentration) in the blood plasma, and the lowest value of clearance. The half-life of MI-538 is about 1.6 h. MI-538 has also high oral bioavailability (~50%)[1]. | [storage]
Store at -20°C | [References]
[1] Borkin D, et al. Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL). J Med Chem. 2016 Feb 11;59(3):892-913. DOI:10.1021/acs.jmedchem.5b01305 |
|
|